high-grade glioma
Conditions
Interventions
Sponsors
First Hospital of Jilin University Department of Radiation
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Patients who meet the following criteria will be eligible for study entry: 1) Patients who had received operation, and had a histopathological diagnosis of malignant glioma; 2) Patients who had received the treatment of standard regimen with radiotherapy with concomitant and adjuvant temozolomide; 3) Patients who had been diagnosed as recurrent malignant glioma confirmed by imaging and pathology; 4) Male and female patients aged between 18 and 70 years; 5) KPS more than 40; 6) No obvious blood routine and biochemical abnormalities confirmed by laboratory examination; 7) No other severe chronic diseases.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: The following patients will be excluded from the study: 1) Pseudo progress can not be excluded according to the clinical manifestations combined with the imaging findings or dynamic recheck; 2) The presence of leptomeningeal metastasis confirmed by imaging findings or cerebrospinal fluid cytological examination; 3) Patients who had the history of severe nervous system disease, or accompanied with severe neurocognitive dysfunction; 4) Patients with poor compliance, or for other reasons, the researchers considered unsuitable to participate in this clinical study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;therapeutic response; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse reaction; | — |
Countries
China
Contacts
Public ContactLihua Dong
Outcome results
None listed